Unanswered questions--drug-eluting stents and the risk of late thrombosis
about
Macromolecular approaches to prevent thrombosis and intimal hyperplasia following percutaneous coronary interventionThe data extraction and longitudinal trend analysis network study of distributed automated postmarket cardiovascular device safety surveillanceSurvival advantage in Medicare patients receiving drug-eluting stents compared with bare metal stents: real or artefactual?Risk score to predict serious bleeding in stable outpatients with or at risk of atherothrombosis.An evaluation of a distributed medical device safety surveillance system: the DELTA network studyEnhancement of endothelialisation of coronary stents by laser surface engineering.Increased artery wall stress post-stenting leads to greater intimal thickening.Comparison of bare metal stent and paclitaxel-eluting stent using a novel rat aorta stent modelClinical evidence of interaction between clopidogrel and proton pump inhibitorsMedical device postapproval safety monitoring: where does the United States stand?Rosuvastatin reduces neointima formation in a rat model of balloon injury.Cost-effectiveness modelling of percutaneous coronary interventions in stable coronary artery disease.Who is responsible for evaluating the safety and effectiveness of medical devices? The role of independent technology assessment.Anti-inflammatory effects of arsenic trioxide eluting stents in a porcine coronary model.Drug-Eluting Versus Bare-Metal Stents During PCI in Patients With End-Stage Renal Disease on DialysisAntiplatelet therapy in the era of drug-eluting stents: current and future perspectives.Comparison of rates of safety issues and reporting of trial outcomes for medical devices approved in the European Union and United States: cohort study.Safety of temporary and permanent suspension of antiplatelet therapy after drug eluting stent implantation in contemporary "real-world" practiceLong-term survival and repeat coronary revascularization in dialysis patients after surgical and percutaneous coronary revascularization with drug-eluting and bare metal stents in the United States.Off-label use of stents: bare-metal versus drug-eluting stents.From basic biology to randomized clinical trial: the Beta Radiation for Arteriovenous Graft Outflow Stenosis (BRAVO II)Tissue-engineered endothelial cell layers on surface-modified Ti for inhibiting in vitro platelet adhesion.A clinical evaluation of the ProNOVA XR polymer-free sirolimus eluting coronary stent system in the treatment of patients with de novo coronary artery lesions (EURONOVA XR I study).Automated surveillance to detect postprocedure safety signals of approved cardiovascular devices.Reporting of harm in randomized controlled trials evaluating stents for percutaneous coronary intervention.Bioabsorbable stent quo vadis: a case for nano-theranostics.Drug-eluting balloon: new tool in the box.Long-term effectiveness and safety of sirolimus drug-eluting stents.Coronary drug-eluting stents: from design optimization to newer strategies.Measuring cardiac waste: the premier cardiac waste measures.Advances and innovations in revascularization of extracranial vertebral artery.Registry-Based Prospective, Active Surveillance of Medical-Device Safety.Can We Identify Minority Patients at Risk of Nonadherence to Antiplatelet Medication at the Time of Coronary Stent Placement?Spontaneous resolution of coronary artery pseudoaneurysm consequent to percutaneous intervention with paclitaxel-eluting stent.Advances in drug eluting stents - focus on the Endeavor(®) zotarolimus stent.Three-Year Clinical Outcomes of a Polymer-Free Paclitaxel-Eluting Microporous Stent in Real-World Practice: Final Results of the Safety and Efficacy Registry of the Yinyi Stent (SERY-I).Adiponectin induces vascular smooth muscle cell differentiation via repression of mammalian target of rapamycin complex 1 and FoxO4.Accelerated Recovery of Endothelium Function after Stent Implantation with the Use of a Novel Systemic Nanoparticle Curcumin.One-year clinical outcome of a randomized trial of polymer-free paclitaxel-eluting stents versus biodegradable polymer-based rapamycin-eluting stents in patients with coronary heart disease.Percutaneous revascularization of grafts versus native coronary arteries in postcoronary artery bypass graft patients.
P2860
Q28654633-0C19CD25-BA91-4ED3-81F6-25139BA1672FQ30876776-7EE20C3B-6E6B-431D-8F4C-119211736E7AQ33553921-978C6DDD-7E17-42CF-B992-307D9F8A52D7Q33849056-568EEB04-BB64-4662-853B-93B1AC9F9ED2Q34756859-2831453A-F708-4F16-97D1-C2253B7FF9FFQ34987708-575CEBBB-1578-4F35-8041-72362718299EQ35012092-07F5ACB8-C927-403F-8AF0-D032A05FC420Q35013930-F99A1CF8-879C-447D-AAB2-DDEF4583A0F7Q35033722-8EF2424D-83B8-439F-A00E-E7BA177B1672Q35270861-5D0CB352-6249-4F6A-AABB-44BB89CF0CF6Q35961612-7979FFAC-88E0-41A4-8149-2B5E0F2DC7C1Q36204864-CA6191E0-3F15-4B41-99FB-D27279D16AE4Q36293539-FFE706E8-44B6-4B49-AA85-92BB8A622754Q36635049-CC18764D-7CBB-49C1-8490-0F3726B50439Q36730186-73CE8AAF-6768-4133-B375-7D73CE1ED08EQ36941850-FB00A5FD-1517-4D63-B5F5-B368E6DCBA4CQ37049270-99DE5E87-C0A8-4F83-9ABD-C57F592C22C3Q37134004-74F15307-C643-4960-988D-545AD9B0FDB1Q37156325-3F372C64-CAB5-443C-92B6-E4A98195BA89Q37269384-479E28EF-ADEA-4540-9C02-F20F65D4A505Q37334204-CB4D41B6-3143-4745-8EC0-D95C819EF079Q37386687-EBD2B0D5-B6FE-40E3-80F9-E7F36A13C6FDQ37386891-FCE16FEB-BF60-4264-8E2F-335BF31BCBFCQ37458616-D5C7B900-7FD7-4D2A-8147-718D35F1F671Q37469343-4D629FE9-D3F9-428E-8605-895997D2774EQ37663672-9BE927E8-8EE2-4B2C-AB74-9B21156441BFQ37737338-230372F2-AF63-47A2-9F59-B1A301748CBDQ38037074-B0956187-E80D-4078-8D8A-3D18156E9EE4Q38109113-6B7F2327-3896-4336-87C3-C7C995A24BDDQ38110359-E9CE2DD9-9ECE-45E9-8B05-AB6EF060EBF3Q38176779-BD543B07-A736-49C7-8D31-903CDD25E15DQ39000188-B21A3220-0A6E-44E4-B5C8-9596A2A6DB31Q39036157-448B224E-56F4-4E4B-A610-856E837954F2Q39420323-FCA20FEC-EC59-46F0-90FB-C114B62C18F5Q41811629-8D852234-C4BE-4176-8FBB-8C5696CD31E7Q41967692-0846C970-8C9B-4B13-AAFD-46611ED921A2Q42058353-5CBE3DB0-F346-4F48-803C-96AD979921BCQ42180347-47942E2C-AA38-4788-91DA-729D050065B6Q44305034-4AB6B66A-425B-47EE-BE6A-3FB4CEAE4FA5Q44696099-C2327CE0-C801-4C32-9D84-02A41FFDC727
P2860
Unanswered questions--drug-eluting stents and the risk of late thrombosis
description
2007 nî lūn-bûn
@nan
2007 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի մարտին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Unanswered questions--drug-eluting stents and the risk of late thrombosis
@ast
Unanswered questions--drug-eluting stents and the risk of late thrombosis
@en
Unanswered questions--drug-eluting stents and the risk of late thrombosis
@nl
type
label
Unanswered questions--drug-eluting stents and the risk of late thrombosis
@ast
Unanswered questions--drug-eluting stents and the risk of late thrombosis
@en
Unanswered questions--drug-eluting stents and the risk of late thrombosis
@nl
prefLabel
Unanswered questions--drug-eluting stents and the risk of late thrombosis
@ast
Unanswered questions--drug-eluting stents and the risk of late thrombosis
@en
Unanswered questions--drug-eluting stents and the risk of late thrombosis
@nl
P3181
P356
P1476
Unanswered questions--drug-eluting stents and the risk of late thrombosis
@en
P2093
William H Maisel
P3181
P356
10.1056/NEJMP068305
P407
P577
2007-03-08T00:00:00Z